Abstract:Microsatellite instability high (MSI-H) tumors are marked by 30% or more mutations in microsatellite regions and are generated by somatic or germline alterations in DNA mismatch repair machinery. Despite a high tumor mutational burden, MSI-H tumors do not frequently harbor mutations in TP53. Notably, a frameshift mutation (p.K15fs) in the gene RPL22 is among the most recurrent mutations in MSI-H tumors. RPL22 and its paralog, RPL22L1, form part of the large subunit of the 60S ribosome and are known to affect protein synthesis as well as splicing of genes and transcription factors that affect development and tumorigenesis. Here we explore the result of RPL22 loss on the regulation of MDM4, an upstream target of p53. MDM4 protein expression is mediated through alternative mRNA splicing of its sixth exon, which leads to two isoforms, the exon 6-inclusive MDM4-FL and the exon 6-exclusive MDM4-S, which is prone to degradation. To date, no mutational events have been associated with this alternative splicing event. We show the prevalence of RPL22fs mutations is more than 70% in certain MSI-H cell lines (e.g. colon, endometrial) and tumors (e.g. stomach adenocarcinoma) in the CCLE and TCGA. RPL22 copy number loss and RPL22 frameshift mutations are strongly correlated with MDM4 exon 6 inclusion in TCGA samples, and RPL22 knockout increases MDM4 exon 6 inclusion and MDM4 protein in multiple cell lines. RPL22 loss increases cell proliferation and augments resistance to the MDM inhibitor Nutlin-3a. Downstream targets of p53 (p21, BBC3) are downregulated due to RPL22 loss and Nutlin-3a inhibition, suggesting mutation of RPL22 and subsequent overexpression of MDM4 promotes resistance to Nutlin-3a. CLIP-seq revealed that RPL22 binds the MDM4 3'-UTR. We find that RPL22 loss is associated with an alternative 3'-splicing event in RPL22L1 adjacent to exon 3 and results in the expression of the full-length transcript of RPL22L1. In summary, we identify RPL22 as a key modulator of MDM4 splicing through an alternative splicing switch in exon 6. Furthermore, RPL22 represses the expression of its paralog, RPL22L1, by mediating the splicing of a cryptic exon corresponding to a truncated functional transcript. Therefore, we propose that damaging mutations in RPL22 drive oncogenic MDM4 induction and reveal a common splicing circuit in MSI-H tumors that may inform therapeutic targeting of the MDM4-p53 axis and oncogenic RPL22L1 induction. Our results also suggest that the presence of RPL22 may act as a rheostat to maintain MDM4 exon 6 skipping under normal cellular contexts. Citation Format: Hannah N. Weinstein, Kevin Hu, Lisa Fish, Yih-An Chen, Paul Allegakoen, Keliana S. Hui, Julia H. Pham, Maria B. Baco, Hanbing Song, Andrew O. Giacomelli, Francisca Vazquez, Mahmoud Ghandi3, Hani Goodarzi, Franklin W. Huang. RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1256.

Ribosomal RNA transcription governs splicing through ribosomal protein RPL22

The ribosomal protein L22 binds the pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress

RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4

Ribosomal protein L8 regulates the expression and splicing pattern of genes associated with cancer-related pathways

Steering research on mRNA splicing in cancer towards clinical translation

Disruption of RNA Splicing Increases Vulnerability of Cells to DNA-PK Inhibitors

The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress

Abstract 5650: RNA regulatory disruption by 3'-dATP: A novel approach to inhibit ribosome biogenesis in cancer

USP42 drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis

SRSF2 plays an unexpected role as reader of m 5 C on mRNA, linking epitranscriptomics to cancer

Targeting Dysregulated Splicing Factors in Cancer: Lessons Learned from RBM10 Deficiency.

RNA splicing dysregulation and the hallmarks of cancer

The PRMT5-splicing axis is a critical oncogenic vulnerability that regulates detained intron splicing

An Integrative Analysis of Colon Cancer Identifies an Essential Function for PRPF6 in Tumor Growth

Hereditary Retinoblastoma Ipsc Model Reveals Aberrant Spliceosome Function Driving Bone Malignancies

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations

Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicing

Abstract 1256: RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4

Pathogenic proteotoxicity of cryptic splicing is alleviated by ubiquitination and ER-phagy

TTF1 control of LncRNA synthesis delineates a tumor suppressor pathway directly regulating the ribosomal RNA genes